, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The batches of Pfizer-BioNTech vaccines, available in the US and Canada, appear to expire in February. Now Pfizer’s CEO has announced (Jan 10, 2022) that a new vaccine will be available in March. By the next day (Jan 11, 2022), WHO said that vaccine makers need to take into consideration Omicron and the need for vaccines that take into account multiple variants of concern (VOCs).

Did the notorious University of North Carolina, Chapel Hill, Baric Lab, which previously turned a bat coronavirus into a human coronavirus, which could cause an epidemic (and pandemic), and has been connected to the Wuhan Institute of Virology, get their vaccine patent approved? We haven’t found the record of it. Nonethless, Pfizer CEO Bourla’s description appears to correspond to the patent. The UNC Chapel Hill-Baric claim to have “developed an mRNA vaccine that protected mice against a range of coronaviruses.” And, allegedly, “the results point the way toward a universal coronavirus vaccine that could prevent future pandemics” (NIH news release July 20, 2021).

Bourla claims that these “vaccines” will be effective against Omicron and other variants.
“Pfizer CEO Bourla: Omicron-specific Covid vaccine will be ready by March”
January 10, 2022

Link: https://youtu.be/oR8DITTTkNI

In case you missed it, they’ve been giving people in the US and Canada expired vaccines since last summer. Both Canada and the US appear to have had batches of Pfizer-BioTech which expired in February and they had extended use by three months: “vials of Pfizer-BioNTech COVID-19 Vaccine with an expiry date of August 2021 through February 2022 printed on the label may remain in use for 3 months beyond the printed date as long as all approved storage conditions have been maintained”. https://archive.vn/MnNTM

The Philadelphia PA, Dept. of Public Health, appears to be misleading people in its announcement about using BioNTech Pfizer vaccine beyond the expiration date. The vaccine available in the US was/is Pfizer-BioNTech and not Comirnaty. Thus, it’s Pfizer-BioNTech whose batches expire in February: “Cartons and vials of Pfizer-BioNTech’s Comirnaty vaccine may remain in use for 3 months beyond the printed date as long as authorized storage conditions (-90°C to -60°C or -130°F to -76°F) have been maintained. Frozen vials stored at -25°C to -15°C and refrigerated vials stored at 2°C to 8°C are NOT eligible for extensionhttps://archive.is/uQmA4 The latest vial expiration date listed in their chart is the same as in Canada – February 2022 with expiration date extended to May 2022.

In October of 2020, the University of North Carolina, Chapel Hill, filed provisional patents for David R. Martinez and Ralph Baric, as co-inventors (US provisional application no. 63/106,247 filed on 27 October 2020) “for the chimeric vaccine constructs and their applications”. Martinez et al., Science 373, 991–998 (2021) 27 August 2021 https://pubmed.ncbi.nlm.nih.gov/34214046/. According to the article, Facebook owner Zuckerberg, and his wife (Chan), were involved in the funding. It also included BioNTech funding. While BioNTech is the ostensible partner of Pfizer, the BioNTech mRNA vaccine Comirnaty was given a license, whereas Pfizer is still on an EUA. Looks like more potential money for BioNTech investors Thomas and Andreas Struengmann who, because of the mRNA vaccine, are now the richest Germans. Their maternal grandfather was one of the German General Kruegers, almost certainly a Nazi, as their mother was born in 1922 and the details appear hidden. The Struengmann father was a (Lutheran) German doctor in the Nazi period, too. Daszak of EcoHealth Alliance’s Ukrainian father appears to have fought with the Nazi SS. Did Baric’s father fight with the Croatian SS? While one may not choose the family into which one is born, one can help acting like them.

According to the article, funding-support for their project included Burroughs Wellcome Fund (Postdoctoral Enrichment Program Award); Hanna H. Gray Fellowship from the Howard Hugues Medical Institute; NIH NIAID T32 AI007151; NIAID F32 AI152296; Chan Zuckerberg Initiative; North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill, with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly; National Institute of Allergy and Infectious Diseases (NIAID), NIH, US Department of Health and Human Services awards U01 AI149644, U54 CA260543, AI157155, and AI110700; AI124429 and a BioNTech SRA; as well as an animal models contract from the NIH (HHSN272201700036I).

News Release excerpt: 
Experimental vaccine protects against multiple coronaviruses, July 20, 2021 

At a Glance

* By combining parts of spike proteins from different coronaviruses, researchers developed an mRNA vaccine that protected mice against a range of coronaviruses.

* The results point the way toward a universal coronavirus vaccine that could prevent future pandemics…

Both SARS-CoV and SARS-CoV-2 are Sarbecoviruses. Bats harbor other Sarbecoviruses that could spread to humans and cause future pandemics. Thus, there is a need for a vaccine that could protect against a range of Sarbecoviruses. 

Some current vaccines against SARS-CoV-2, like the Pfizer and Moderna vaccines, are mRNA vaccines. These contain messenger RNA (mRNA) that directs the body’s cells to make a viral protein, which elicits an immune response. A team of researchers led by Drs. David Martinez and Ralph Baric at the University of North Carolina at Chapel Hill set out to design an mRNA vaccine that would be effective against several Sarbecoviruses.

NIH’s National Institute for Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) supported the work. Results were described in Science on June 22, 2021…https://www.nih.gov/news-events/nih-research-matters/experimental-vaccine-protects-against-multiple-coronaviruses

Read more: https://miningawareness.wordpress.com/2021/08/27/wuhan-connected-nc-baric-lab-that-converted-a-bat-coronavirus-to-a-pandemic-capable-human-coronavirus-claims-to-have-new-mrna-vaccine-against-multiple-coronaviruses-funders-include-nih-niaid-nci-ch/

WHO statement, on January 11th:
Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)
11 January 2022 Statement

Key messages:
* WHO has established the Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) to review and assess the public health implications of emerging SARS-CoV-2 Variants of Concern (VOC) on the performance of COVID-19 vaccines and to provide recommendations to WHO on COVID-19 vaccine composition, as needed.
* In the context of the circulation of Omicron SARS-CoV-2 Variant of Concern, the TAG-CO-VAC urges broader access globally to current COVID-19 vaccines for primary series and booster doses, in the hope that this also mitigates the emergence and impact of new VOCs.
* The TAG-CO-VAC is considering the strain composition of COVID-19 vaccines, and encourages vaccine developers to gather data on a small scale on the breadth and magnitude of immune response for monovalent and multivalent vaccines against VOCs – this data would then be considered in a broader decision-making framework on vaccine composition by the TAG-CO-VAC

Composition of current and future COVID-19 vaccines
The TAG-CO-VAC considers that COVID-19 vaccines that have high impact on prevention of infection and transmission, in addition to the prevention of severe disease and death, are needed and should be developed. Until such vaccines are available, and as the SARS-CoV-2 virus evolves, the composition of current COVID-19 vaccines may need to be updated, to ensure that COVID-19 vaccines continue to provide WHO-recommended levels of protection against infection and disease[4] by VOCs, including Omicron and future variants.
The TAG-CO-VAC will consider a change in vaccine composition:
* to ensure that vaccines continue to meet the criteria established in WHO’s Target Product Profile for COVID-19 vaccines, including protection against severe disease
* to improve vaccine-induced protection.

To that aim, COVID-19 vaccines need to:
* be based on strains that are genetically and antigenically close to the circulating SARS-CoV-2 variant(s);
* in addition to protection against severe disease and death, be more effective in protection against infection thus lowering community transmission and the need for stringent and broad-reaching public health and social measures;
* elicit immune responses that are broad, strong, and long-lasting in order to reduce the need for successive booster doses.

In line with this approach, there are many options to consider:
* a monovalent vaccine that elicits an immune response against the predominant circulating variant(s), although this option faces the challenge of the rapid emergence of SARS-CoV-2 variants and the time needed to develop a modified or new vaccine;
* a multivalent vaccine containing antigens from different SARS-CoV-2 VOCs;
* a pan SARS-CoV-2 vaccine: a more sustainable long-term option that would effectively be variant-proof.

In the interim, the TAG-CO-VAC encourages COVID-19 vaccine manufacturers to generate and provide data on performance of current and Omicron-specific COVID-19 vaccines, including the breadth, magnitude, and durability of humoral and cell mediated immune responses to variants through monovalent and/or multivalent vaccines. These data will be considered in the context of the framework mentioned above to inform the TAG-CO-VAC decisions when changes to vaccine composition may be required. It would be important for vaccine manufacturers to take steps in the short-term for the development and testing of vaccines with predominant circulating variants and to share these data with the TAG-CO-VAC and other relevant WHO expert committees. Vaccine manufacturers are also encouraged to provide such data for any novel and broadly reactive SARS-CoV-2 vaccines that are developed”. Read more here: https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition